We are a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. We target our development programs for the treatment of specific subsets of cancer populations, and simultaneously develop, with partners, companion diagnostics intended to direct a compound in development to the population that is most likely to benefit from its use. Our first commercial product and lead product candidate, rucaparib, is an oral, small molecule poly ADP-ribose polymerase, or PARP, inhibitor of PARP1, PARP2 and PARP3. We hold global development and commercialization rights for rucaparib. RubracaTM (rucaparib) is the first and only oral, small molecule PARP inhibitor approved in the United States by the FDA as monotherapy treatment of advanced ovarian cancer in women with deleterious germline or somatic BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy based on an FDA-approved companion diagnostic for Rubraca. Rucaparib is being explored in a variety of solid tumor types with significant BRCA and BRCA-like populations, including ovarian, prostate, breast, pancreatic, gastroesophageal, bladder and lung cancers. In addition, we have two other product candidates: lucitanib, an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors (VEGFR) 1-3, platelet-derived growth factor receptors (PDGFR) alpha and beta and fibroblast growth factor receptors (FGFR) 1-3, and rociletinib, an oral mutant-selective inhibitor of epidermal growth factor receptor (ñEGFRî). Clinical development for each of these candidates has ceased and we continue to provide drug to patients whose clinicians recommend continuing therapy. We maintain certain development and commercialization rights for lucitanib and global development and commercialization rights for rociletinib.